Search
Olsalazine
go.drugbank.com/drugs/DB01250ApprovedOlsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA).
Categories: Non COX-2 selective NSAIDSDasatinib
go.drugbank.com/drugs/DB01254ApprovedInvestigational[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. … [A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region
Synonyms: N-(2-CHLORO-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamideCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexLapatinib
go.drugbank.com/drugs/DB01259ApprovedInvestigationalLapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. … Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer.
Synonyms: N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamineCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesPaliperidone
go.drugbank.com/drugs/DB01267ApprovedInvestigationalIt has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. … Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.
Synonyms: 9-hydroxyrisperidoneCategories: P-glycoprotein inhibitors, P-glycoprotein substratesSunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalThese include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). … Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor.
Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic IndexProducts: DOSTINIB® 25MG, DOSTINIB® 50MGHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigationalOriginally developed in the 1950s as a malaria treatment, hydralazine showed antihypertensive ability and was soon repurposed. … [A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications.
Synonyms: 6-Hydralazine, 1-HydrazinophthalazineInternational brands: Cesoline W, Cesoline YPirbuterol
go.drugbank.com/drugs/DB01291ApprovedWithdrawnPirbuterol is a beta-2 adrenergic bronchodilator. … ,5†-adenosine monophosphate (c-AMP).
Categories: Adrenergic beta-2 Receptor Agonists, Selective Beta 2-adrenergic AgonistsBevantolol
go.drugbank.com/drugs/DB01295InvestigationalBevantolol is a beta-1 adrenoceptor antagonist that has been shown to be as effective as other beta blockers for the treatment of angina pectoris and hypertension. … Mechanism of Action Animal experiments confirm both agonist and antagonist effects on alpha-receptors, in addition to antagonist activity at beta-1 receptors.
Synonyms: 1-((2-(3,4-dimethoxyphenyl)ethyl)amino)-3-(3-methylphenoxy)-2-propanol, 1-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-3-m-tolyloxy-propan-2-olCategories: Cytochrome P-450 Substrates, Adrenergic alpha-1 Receptor AntagonistsSt. John's Wort
go.drugbank.com/drugs/DB01323ApprovedNutraceuticalMixtures: S. R. FormulaCategories: P-glycoprotein inducers, Cytochrome P-450 SubstratesCefazolin
go.drugbank.com/drugs/DB01327ApprovedInvestigationalA semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Synonyms: (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidMixtures: CEFAMEZIN 250 MG IM ENJEKTABL TOZ İÇEREN FLAKON, 1 ADET, CEFAMEZIN 500 MG IM ENJEKTABL TOZ İÇEREN FLAKON, 1 ADET